To genetically define whether ACLY is necessary for PD-1-deficient lymphoma growth in vivo, we disrupted Acly in transformed ITK–SYK+PD-1− T cells using CRISPR–Cas9-mediated gene editing and transplanted these cells into syngeneic wild-type hosts (Fig. 4f). This evidence concerns the gene ACLY and lymphoma.